Iterum Therapeutics PLC (NASDAQ:ITRM) – Research analysts at G.Research boosted their FY2020 EPS estimates for shares of Iterum Therapeutics in a research report issued on Tuesday, January 21st. G.Research analyst K. Kedra now expects that the company will earn ($5.00) per share for the year, up from their previous forecast of ($5.10). G.Research has a “Sell” rating on the stock. G.Research also issued estimates for Iterum Therapeutics’ FY2021 earnings at ($3.90) EPS, FY2022 earnings at ($4.90) EPS and FY2023 earnings at ($2.80) EPS.
Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($2.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.61) by ($0.54).
Shares of ITRM opened at $2.75 on Thursday. The firm has a market cap of $41.04 million, a P/E ratio of -0.38 and a beta of 2.21. Iterum Therapeutics has a 12-month low of $1.68 and a 12-month high of $9.30. The company’s 50-day moving average price is $3.59 and its 200 day moving average price is $4.76. The company has a current ratio of 0.99, a quick ratio of 0.99 and a debt-to-equity ratio of 0.44.
A hedge fund recently raised its stake in Iterum Therapeutics stock. Granahan Investment Management Inc. MA raised its position in Iterum Therapeutics PLC (NASDAQ:ITRM) by 4.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 242,226 shares of the company’s stock after purchasing an additional 9,360 shares during the quarter. Granahan Investment Management Inc. MA owned 1.74% of Iterum Therapeutics worth $1,398,000 at the end of the most recent quarter. Institutional investors and hedge funds own 42.85% of the company’s stock.
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Featured Article: How does a security become overbought?
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.